Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry.
about
The value of open access and a patient centric approach to oral oncolytic utilization in the treatment of Chronic Myelogenous Leukemia: A U.S. perspective.Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real-world data from the Swedish MPN Registry.Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).Asparaginase induces apoptosis and cytoprotective autophagy in chronic myeloid leukemia cells.The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma - a Swedish population-based study.Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trialsChronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000-2013Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapyManaging chronic myeloid leukaemia in the elderly with intermittent imatinib treatmentQuality of Life and Long-Term Therapy in Patients with Chronic Myeloid LeukemiaSecondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV.Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort.Population-Based Testing and Treatment Characteristics for Chronic Myelogenous Leukemia.Epidemiology of chronic myeloid leukaemia: an update.The impact of socio-economic factors on treatment choice and mortality in chronic myeloid leukaemia.Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase.BCR: a new target in resistance mediated by BCR/ABL-315I?Improved survival boosts the prevalence of chronic myeloid leukemia: predictions from a population-based study.Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register.Changes in the survival of older patients with hematologic malignancies in the early 21st century.Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia.Treatment outcome in a population-based, 'real-world' cohort of patients with chronic myeloid leukemia.Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries.Charlson comorbidity index predicts poor outcome in CML patients treated with tyrosine kinase inhibitor.Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia.Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.Functional screen analysis reveals miR-3142 as central regulator in chemoresistance and proliferation through activation of the PTEN-AKT pathway in CML.Chronic myeloid leukemia in the Netherlands: a population-based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012.The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.Chronic myeloid leukemia: room for improvement?Innovation in hematology. Perspectives: CML 2016Chronic Myeloid Leukemia-the Promise of Tyrosine Kinase Inhibitor Discontinuation.An observational study on risk of secondary cancers in chronic myeloid leukemia patients in the TKI era in the United States.Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK's population-based Haematological Malignancy Research Network 2004-15.Modulation of leukotriene signaling inhibiting cell growth in chronic myeloid leukemia.Prognostic discrimination for early chronic phase chronic myeloid leukemia in imatinib era: comparison of Sokal, Euro, and EUTOS scores in Korean population.
P2860
Q30491107-2F65AA3E-E525-435C-943A-8DC900C6EED5Q31169518-587DB0F2-96D8-4725-A553-3B760395CEEAQ35194464-AFA9AD5F-7BB2-456E-8196-D784DD6FAF85Q35551889-2AF92B57-3A4B-4433-9D0B-BDE9D2B2753CQ35832484-614DB67A-8B0B-45B6-9332-B0D4B13C2CBFQ35873909-546D8132-C043-49F2-BCFA-F585AB9C48A3Q35949910-870F9F0D-26EB-48DF-B5D2-AD8BAE801F2AQ36068354-63574B8B-48EE-490E-AADE-D8CC7CBE6962Q36288815-7F66E430-4B87-4DDC-BB27-064A8046C3C2Q36880864-72843512-8DF6-4F1A-BE17-E751553E165BQ36974374-0544ABE7-0831-44AB-9BF6-E771F5A5FDC9Q37517333-9E21B46D-50CB-46B3-BF91-F61AA8D03ED8Q37623651-B6FFA80B-6258-4630-938E-0FFEDD0E4D97Q38392709-E87C68A4-7C22-4E1B-8C96-D031029E76AFQ38403647-DE46D058-A534-4340-96E5-A562C575A87FQ38685803-13A3524A-21E0-4E1B-B645-D033B4D3EB13Q38710583-840A51A5-5E73-4D33-8785-F5DE68B63A56Q38880265-5CC15F1E-EDD9-44DF-86A6-4DF8042214EAQ38913462-945F9E31-2DA5-42B0-ABD9-8BCD1413952EQ38940615-F15EBF9B-1AAB-4DB3-A7AC-52468DF7D622Q39259447-6FAB0D86-AC0B-4004-B1ED-46FDE456C23CQ39446340-24B932D6-39CF-4E5C-B60D-839562F43EA3Q39591396-6E539141-C6E4-4B38-AB4E-4CE21E7C791EQ39779257-8C7AB9FA-DE7E-42CB-9380-CC360F3E9257Q39924810-203F7574-5850-41C1-AB06-D69B514FEF74Q40062215-4AB50DF0-5755-46C8-9B8F-6D3F0F58F960Q40294098-6A57947B-1ED2-46F5-BFFB-1F8D6389816DQ40519438-A826DF77-7BB6-4620-AA79-066E26C5F3C7Q40799115-EB048D4B-49FF-41F0-B45A-F7B379D6A04BQ40821920-F2EE139D-F25B-4D3B-A509-35A4ECFC2FCAQ41082813-921CD659-2B4F-4B9D-B69C-6E634C7D8A3FQ41164222-DB0A2CB6-3D6B-44F3-B3AF-6779520B8365Q41200962-7B49CC60-2A82-4744-BB7E-E5EA588AFBFEQ42348447-8AA62C45-441F-47D5-A1DC-4517818255E2Q42397473-41F8EE5E-A94B-4A47-AB9A-46292A4FF856Q47929120-F0961DAE-04D0-43F5-BB65-B43C573E19BBQ49873738-9B81C91A-25F1-4A32-BEB9-D8C655D8AF7DQ50976585-E3036314-15B8-4FB8-BD66-2A1283531393Q51279012-4D494089-A0CB-44A2-AD52-6E0E63237CF7Q54348857-31C3F6E5-2215-473F-ADDF-61E0189DE694
P2860
Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tyrosine kinase inhibitor usag ...... on-based Swedish CML registry.
@en
Tyrosine kinase inhibitor usag ...... on-based Swedish CML registry.
@nl
type
label
Tyrosine kinase inhibitor usag ...... on-based Swedish CML registry.
@en
Tyrosine kinase inhibitor usag ...... on-based Swedish CML registry.
@nl
prefLabel
Tyrosine kinase inhibitor usag ...... on-based Swedish CML registry.
@en
Tyrosine kinase inhibitor usag ...... on-based Swedish CML registry.
@nl
P2093
P2860
P1433
P1476
Tyrosine kinase inhibitor usag ...... on-based Swedish CML registry.
@en
P2093
Anders Själander
Arta Dreimane
Bengt Simonsson
Berit Markevärn
Claes Malm
Fredrik Sandin
Hans Wadenvik
Johan Richter
Karin Hellström
Kristina Myhr-Eriksson
P2860
P304
P356
10.1182/BLOOD-2013-04-495598
P407
P50
P577
2013-07-10T00:00:00Z